Dialysis device maker NxStage Medical Inc. said Friday that its second-quarter loss narrowed on a revenue boost from the sale of home care products and from its critical care unit.
NxStage lost $8.3 million, or 17 cents per share, compared with a loss of $12.5 million, or 27 cents per share, a year earlier. Revenue rose 21 percent to $44 million from $36.4 million.
Analysts polled by Thomson Reuters expected a loss of 18 cents per share on revenue of $41.1 million.
NxStage said revenue for at-home hemodialysis products rose 37 percent to $20.8 million while critical care revenue grew 27 percent to $6.7 million.
Looking ahead, the company said it expects a third-quarter loss between 15 cents and 18 cents per share on revenue between $43 million and $45 million. Analysts expect a loss of 16 cents per share on revenue of $42.2 million.
For the full year, the company expects a loss of 60 cents to 71 cents per share on revenue between $170 million and $175 million, which is a boost from prior revenue guidance between $163 million to $170 million. Analysts expect a loss of 65 cents per share on revenue of $168.6 million.